Gregory P Fusco, MD, MPH

Epividian, Inc.

Disclosure(s): Gilead: Grant/Research Support; Merck: Grant/Research Support; Theratechnologies: Grant/Research Support; Viiv: Grant/Research Support

Poster(s):

• (P-332) Screening Practices for HIV and Sexually Transmitted Infections During Cabotegravir Long Acting or Daily Oral Pre-Exposure Prophylaxis Use in the US
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-371) Few differences in persistence and virologic outcomes across age groups among CAB+RPV LA users: Findings from the OPERA Cohort
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-383) Reasons for discontinuation of CAB+RPV LA for HIV treatment in the OPERA Cohort: A CHORUS survey of healthcare providers
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET